Feinman Richard D, Pogozelski Wendy K, Astrup Arne, Bernstein Richard K, Fine Eugene J, Westman Eric C, Accurso Anthony, Frassetto Lynda, Gower Barbara A, McFarlane Samy I, Nielsen Jörgen Vesti, Krarup Thure, Saslow Laura, Roth Karl S, Vernon Mary C, Volek Jeff S, Wilshire Gilbert B, Dahlqvist Annika, Sundberg Ralf, Childers Ann, Morrison Katharine, Manninen Anssi H, Dashti Hussain M, Wood Richard J, Wortman Jay, Worm Nicolai
Department of Cell Biology, State University of New York Downstate Medical Center, Brooklyn, New York, USA.
Department of Chemistry, State University of New York Geneseo, Geneseo, NY, USA.
Nutrition. 2015 Jan;31(1):1-13. doi: 10.1016/j.nut.2014.06.011. Epub 2014 Jul 16.
The inability of current recommendations to control the epidemic of diabetes, the specific failure of the prevailing low-fat diets to improve obesity, cardiovascular risk, or general health and the persistent reports of some serious side effects of commonly prescribed diabetic medications, in combination with the continued success of low-carbohydrate diets in the treatment of diabetes and metabolic syndrome without significant side effects, point to the need for a reappraisal of dietary guidelines. The benefits of carbohydrate restriction in diabetes are immediate and well documented. Concerns about the efficacy and safety are long term and conjectural rather than data driven. Dietary carbohydrate restriction reliably reduces high blood glucose, does not require weight loss (although is still best for weight loss), and leads to the reduction or elimination of medication. It has never shown side effects comparable with those seen in many drugs. Here we present 12 points of evidence supporting the use of low-carbohydrate diets as the first approach to treating type 2 diabetes and as the most effective adjunct to pharmacology in type 1. They represent the best-documented, least controversial results. The insistence on long-term randomized controlled trials as the only kind of data that will be accepted is without precedent in science. The seriousness of diabetes requires that we evaluate all of the evidence that is available. The 12 points are sufficiently compelling that we feel that the burden of proof rests with those who are opposed.
当前的建议无法控制糖尿病的流行,流行的低脂饮食未能有效改善肥胖、心血管风险或总体健康状况,而且关于常用糖尿病药物一些严重副作用的报道不断,与此同时,低碳水化合物饮食在治疗糖尿病和代谢综合征方面持续取得成功且无明显副作用,这些都表明需要重新评估饮食指南。限制碳水化合物对糖尿病的益处是即时的且有充分记录。对其疗效和安全性的担忧是长期的且基于推测而非数据。饮食中限制碳水化合物能可靠地降低高血糖,无需减重(尽管对减重仍最为有利),还能减少或停用药物。它从未显示出与许多药物相当的副作用。在此,我们列出12条证据,支持将低碳水化合物饮食作为治疗2型糖尿病的首选方法以及1型糖尿病最有效的药物辅助手段。它们代表了记录最完备、争议最小的结果。坚持认为只有长期随机对照试验数据才会被接受,这在科学界并无先例。糖尿病的严重性要求我们评估所有可得证据。这12条证据极具说服力,以至于我们认为举证责任在于反对者。